Kangfang Biotech (09926.HK): The second indication of Yidafang (Yivostar, PD-1/VEGF) has been approved by the NMPA for first-line treatment of PD-L1 positive NSCLC.

Zhito Financial News App: KANG FANG Biology (09926.HK) announced that the company's independently developed global first-in-class dual-specificity antibody drug Yidafang (Ivosi, PD-1/VEGF) as a single agent for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 positivity (TPS1%), epidermal growth factor receptor (EGFR) gene mutation negativity, and anaplastic lymphoma kinase (ALK) negativity has been granted approval for market authorization by the National Medical Products Administration (NMPA) in China. This is the second indication for which Ivosi has been approved for market authorization, allowing Chinese patients to "be the first to use the world's best treatment options."